RECRUITINGOBSERVATIONAL
Effectiveness and Tolerability of Eptinezumab
Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study
About This Trial
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
- Good compliance to study procedures;
- Availability of headache diary at least of the preceding months before enrolment;
- At least 8 monthly migraine days.
Who Should NOT Join This Trial:
- Subjects with contraindications for use of eptinezumab;
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding
- Changes in preventive treatments in the month before the first administration of eptinezumab
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
* Good compliance to study procedures;
* Availability of headache diary at least of the preceding months before enrolment;
* At least 8 monthly migraine days.
Exclusion Criteria:
* Subjects with contraindications for use of eptinezumab;
* Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
* medical comorbidities that could interfere with study results;
* Pregnancy and breastfeeding
* Changes in preventive treatments in the month before the first administration of eptinezumab
Treatments Being Tested
DRUG
Eptinezumab 100 or 300 mg ev
Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Locations (2)
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence, Italy
AOU Policlinico Di Modena
Modena, Italy